Labcorp Holdings Inc. reported a revenue of $13.95 billion for the fiscal year ending December 31, 2025, marking a 7.2% increase from $13.01 billion in 2024. This growth was attributed to a combination of organic revenue growth of 4.4%, acquisitions contributing 2.5%, and favorable foreign currency translation effects of 0.4%. The Diagnostics (Dx) segment generated $10.88 billion, up 7.2% from the previous year, while the Biopharma Laboratory Services (BLS) segment saw revenues rise by 6.0% to $3.10 billion. The overall operating income increased by 27.4% to $1.38 billion, driven by improved operational efficiencies and revenue growth.
In terms of operational metrics, the Dx segment experienced a 3.7% increase in total volume, with requisitions rising by 2.2% organically and an additional 1.5% from acquisitions. The BLS segment also benefited from organic growth, which accounted for 4.0% of its revenue increase. The company launched over 130 new tests in 2025, expanding its offerings in high-growth areas such as oncology and neurology, which collectively support more than half of the clinical trials managed by its Central Laboratory business.
Strategically, Labcorp completed the spin-off of Fortrea Holdings Inc. on June 30, 2023, which has allowed the company to focus on its core laboratory services. The company also made significant investments in acquisitions, totaling $582 million in 2025, aimed at enhancing its service offerings and expanding its geographic reach. Notably, Labcorp acquired a minority stake in SYNLAB, a leader in medical diagnostic services in Europe, further solidifying its international presence.
The company’s workforce comprised nearly 71,000 employees across 100 countries, with 89% based in the U.S. and Canada. Labcorp's employee engagement initiatives included the launch of a global program to enhance inclusivity and recognition, as well as investments in employee well-being and development. The company also reported a decrease in selling, general, and administrative expenses as a percentage of revenues, reflecting improved operational efficiency.
Looking ahead, Labcorp anticipates continued growth driven by advancements in technology and an expanding portfolio of specialty tests. However, the company also faces potential challenges from changes in healthcare regulations and reimbursement models, particularly following the enactment of the One Big Beautiful Bill Act (OBBBA) in July 2025, which may impact the utilization of its diagnostic testing services. Despite these uncertainties, Labcorp remains optimistic about its strategic direction and the ongoing demand for its laboratory services.
About LABCORP HOLDINGS INC.
Labcorp Holdings Inc. is a global leader in diagnostic and biopharmaceutical laboratory services. It provides routine and specialty testing, drug development, and clinical trial support to healthcare providers, pharmaceutical companies, and researchers across approximately 100 countries. Leveraging advanced science, technology, and a broad network, it offers innovative testing solutions, supports drug approval processes, and enhances healthcare decision-making worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.